Porous egg microparticles for controllable drug delivery and oncotherapy

Abstract

Baicalein (BAI) extracted from Chinese herb has been proved to increase the sensitivity of tumor cells to gemcitabine (GEM) and effectively solve the problem of drug resistance of tumor cells. Nevertheless, intravenous administration often leads to intolerance of patients and side effects. In this paper, we introduced egg-based porous microparticles for controllable drug delivery and oncotherapy, which avoided frequent intravenous administration. The interconnected porous structure endowed the microparticles with the capacity of loading sufficient drugs and releasing in a controllable way by adjusting the concentration and proportion of egg white and yolk. We have demonstrated that the cell viability of drug delivery system group was less than 50%, while the single drug group was more than 70%, which indicated that the co-delivery of GEM and BAI could significantly reduce the proliferation of cells. These features indicated that the egg porous microparticles are ideal for controllable drug delivery and oncotherapy.

Keywords

delivery / egg hydrogel / inverse opal / microparticle

References

[1] Delman KA. Introducing the "virtual tumor board" series in CA: a cancer journal for clinicians. CA Cancer J Clin. 2020; 70(2): 77.

[2] Lu L, Niu Z, Chao Z, Fu C, Chen K, Shi Y. Exploring the therapeutic potential of ADC combination for triple-negative breast cancer. Cell Mol Life Sci. 2023; 80(12): 350.

[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[4] Yang Z, Zhang Q, Yu L, Zhu J, Cao Y, Gao X. The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J Ethnopharmacol. 2021; 264: 113249.

[5] Zhang C, Sui X, Jiang Y, Wang X, Wang S. Antitumor effects of icaritin and the molecular mechanisms. Discov Med. 2020; 29(156): 5-16.

[6] Li T, Tao Z, Zhu Y, et al. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. Cell Death Dis. 2021; 12(7): 684.

[7] Wang B, Sun T, Zhao Y, et al. A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nat Commun. 2022; 13(1): 4025.

[8] Mohammad ZH, Ahmad F. Nanocoating and its application as antimicrobials in the food industry: a review. Int J Biol Macromol. 2023; 254: 127906.

[9] Nezamdoost-Sani N, Khaledabad MA, Amiri S, Phimolsiripol Y, Khaneghah AM. A comprehensive review on the utilization of biopolymer hydrogels to encapsulate and protect probiotics in foods. Int J Biol Macromol. 2023; 127907: 127907.

[10] Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022; 23(5): 265-280.

[11] Jain KK. An overview of drug delivery systems. Methods Mol Biol. 2020; 2059: 1-54.

[12] Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021; 5(9): 951-967.

[13] Gao M, Zehua Han X, Zhang XZ, Peng L, Zhao Y, Sun L. Construction of double-shelled hollow Ag2S@Polydopamine nanocomposites for fluorescence-guided, dual stimuli-responsiv. drug delivery and photothermal therapy. Nanomaterials. 2022; 12(12): 2068.

[14] Minjie Gao, Jiyuan Du, Zehua Han, Zhihua Wang, Yanbao Zhao, Xueyan Zou, Lei Sun. Precise preparation of various morphological silver sulfide nanostructures, investigation of formation mechanism, and comparative study of Photothermal performance for cancer treatment. Part Part Syst Charact, 2022, 39: 2100240.

[15] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20(2): 101-124.

[16] Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12): 1078-1094.

[17] Chen YL, Bao CJ, Duan JL, Xie Y, Lu WL. Overcoming biological barriers by virus-like drug particles for drug delivery. Adv Drug Deliv Rev. 2023; 115134: 115134.

[18] Huang P, Deng H, Wang C, Zhou Y, Chen X. Cellular trafficking of nanotechnology-mediated mRNA delivery. Adv Mater. 2023; 13(6): e2307822.

[19] Hao JN, Ge K, Chen G, Dai B, Li Y. Strategies to engineer various nanocarrier-based hybrid catalysts for enhanced chemodynamic cancer therapy. Chem Soc Rev. 2023; 52: 7707-7736.

[20] Wu J, Pu K. Leveraging semiconducting polymer nanoparticles for combination cancer immunotherapy. Adv Mater. 2023; 36: e2308924.

[21] Delaney DS, Liew LJ, Lye J, Atlas MD, Wong EYM. Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear. Front Pharmacol. 2023; 14: 1207141.

[22] Wang Y, Li R, Shu W, Chen X, Lin Y, Wan J. Designed nanomaterials-assisted proteomics and metabolomics analysis for in vitro diagnosis. Small. Methods. 2023; 8: e2301192.

[23] Moore TL, Pannuzzo G, Costabile G, et al. Nanomedicines to treat rare neurological disorders: the case of Krabbe disease. Adv Drug Deliv Rev. 2023; 203: 115132.

[24] Yan X, Sha X. Nanoparticle-mediated strategies for enhanced drug penetration and retention in the airway mucosa. Pharmaceutics. 2023; 15(10): 2457.

[25] Utembe W, Andraos C, Gulumian M. Immunotoxicity of engineered nanomaterials and their role in asthma. Crit Rev Toxicol. 2023; 53: 1-15.

[26] Dhiman V, Singh S, Srivastava V, Garg S, Saran AD. Nanomaterials for photo-electrochemical water splitting: a review. Environ Sci Pollut Res Int. 2023.

[27] Zhang H, Chen H, Lu L, Wang H, Zhao YJ, Chai RJ. Natural multifunctional silk microcarriers for noise-induced hearing loss therapy. Adv Sci. 2024; 11(1): e2305215.

RIGHTS & PERMISSIONS

2024 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.